Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • rjohnp
    Member
    • Jan 2013
    • 16

    #1

    DNA Sample tracking

    Hi all,

    a not particularly intensive question here. We recently had a couple of sample identities mixed by our exome sequencing provider (i.e. we got back all our data but some of the .fastq files were misidentified). This is obviously a huge issue.

    I was wondering what sort of approaches were taken in other core labs in order to prevent, or at least catch this sort of error? If we're supposedly moving towards clinical sequencing as a standard this really needs not to happen.

    Thanks for any suggestions.
  • Bukowski
    Senior Member
    • Jan 2010
    • 388

    #2
    I like the fact you assume it was your sequencing provider that mixed up the sequences, and not your lab that mixed up the samples

    I'm only joking, because I'm sure you've gone back and genotyped what you've sent and had your provider genotype the aliquots you sent them but I've had to deal with many situations where we have been sent samples (or data) that is not what the originator claims, at any point in the process where a human is involved there exists the possibility for sample mix up.

    I think the only answer from the lab side is automation. You could have a genotyping panel run on samples as they come in, and checked against e.g. exome results on the way out. It would be great to have some kind of sample barcoding that is applied before capture and library prep is carried out that can be assayed later (I'm a bioinformatician, not running the machines, so no idea how feasible this is).

    Far too often sample mix ups only present on analysis. My favourite, as it is the easiest to pick up and rectify is the trio's where a parent has been swapped for a child.

    Comment

    • rjohnp
      Member
      • Jan 2013
      • 16

      #3
      A valid point of course, but yes, we did check that all.

      Very interesting actually, there are some good articles out there on lab automation, mainly for clinical path labs, some showing that error rates actually go up following automation, at least for a couple of months. The hardware is only as good as the programmer and the user, garbage in, garbage out and all that.

      I guess an issue with ligating an oligo tag onto all your fragmented DNA (I think that's what you're suggesting here) is that you're essentially reducing you're coverage as you will just trim that sequence of on analysis, so say a 6% loss in coverage for a hexamer tag on 100 bp reads. And if you mix up the samples doing that you have no hope...

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
        by SEQadmin2



        CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

        Despite this, “CRISPR helped turn genome editing from a specialized technique into
        ...
        07-31-2026, 11:01 AM
      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Yesterday, 10:13 AM
      0 responses
      14 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-31-2026, 02:55 AM
      0 responses
      27 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-24-2026, 12:17 PM
      0 responses
      20 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-23-2026, 11:41 AM
      0 responses
      19 views
      0 reactions
      Last Post SEQadmin2  
      Working...